insights_auto
Proč je 000739 níž 3,17%?
Prozkoumat hloubějichevron_right
000739:SHE
Apeloa Pharmaceutical Co Ltd
23,81 CN¥
arrow_downward
-3,17%(-0,78) 1D
15. 10., 15:04:03 GMT+8 · CNY
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro 000739…
Otevřít
24,10 CN¥
Max.
24,94 CN¥
Min.
23,60 CN¥
Trž. kap.
28,68 mld.
Prům. obj.
16,22 mil.
Objem
14,07 mil.
Dividenda
1,58 %
Čtvrtletní dividenda
0,09 CN¥
Datum ex dividenda
8. 10. 2026
Ukazatel P/E
32,31
52týd. max.
28,50 CN¥
52týd. min.
14,89 CN¥
EPS
0,74 CN¥
Akcie v oběhu
1,16 mld.
Počet zaměstnanců
7 tis.
Otevřít
24,10 CN¥
Max.
24,94 CN¥
Min.
23,60 CN¥
Trž. kap.
28,68 mld.
Prům. obj.
16,22 mil.
Objem
14,07 mil.
Dividenda
1,58 %
Čtvrtletní dividenda
0,09 CN¥
Datum ex dividenda
8. 10. 2026
Ukazatel P/E
32,31
52týd. max.
28,50 CN¥
52týd. min.
14,89 CN¥
EPS
0,74 CN¥
Akcie v oběhu
1,16 mld.
Počet zaměstnanců
7 tis.
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
TradingView
·
před 24 minutami
TruGolf Holdings (NASDAQ: TRUG) Taps Newly Acquired Polymath to Tokenize Franchise Ownership Records
GlobeNewswire
·
před 37 minutami
Nasdaq Private Market Completes Acquisition of Nasdaq Fund
bloomingbit
·
před 1 hodinou
Nasdaq-Listed Tron Files $200 Million Stock Offering to Fund TRX Purchases
CNN
·
před 4 hodinami
Global tech sell-off deepens as enthusiasm for AI stocks wobbles
Profil
Apeloa Pharmaceutical Co., Ltd., known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China. It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997. Apeloa provides contract development and manufacturing services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas.
Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development. It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing. In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development.
Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006. Wikipedia
Informace o Apeloa Pharmaceutical Co Ltd